Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.

  • Xeris Biopharma Holdings' Profit After Tax rose 10394.59% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7521.91%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.71% up from last year.
  • Xeris Biopharma Holdings' Profit After Tax amounted to $621000.0 in Q3 2025, which was up 10394.59% from -$1.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Profit After Tax's 5-year high stood at $621000.0 during Q3 2025, with a 5-year trough of -$50.8 million in Q4 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Profit After Tax had a median value of -$16.8 million in 2023 and averaged -$18.2 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Profit After Tax crashed by 13237.41% in 2021, and later soared by 10394.59% in 2025.
  • Xeris Biopharma Holdings' Profit After Tax (Quarter) stood at -$50.8 million in 2021, then skyrocketed by 74.54% to -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then surged by 112.15% to $621000.0 in 2025.
  • Its Profit After Tax was $621000.0 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.